TransMedics Group, Inc.
Every calculator, already run for TMDX
Open the full toolkit →You have the numbers on TMDX. Get the argument.
A written report on which of these readings actually decide the outcome for TransMedics Group, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
11 analysts covering TMDXOwnership & short interest
About TransMedics Group, Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanim…
TMDX — frequently asked
Is TMDX a buy right now?
Wall Street's consensus rating on TransMedics Group, Inc. is Buy across 11 analysts, with a mean price target of $106.00 (+30% vs. the current $81.58). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is TMDX overvalued?
TMDX trades at 18.7x trailing earnings, against a DCF fair value of $46 per share. The current price implies 14% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is TMDX's next earnings date?
TransMedics Group, Inc. is next scheduled to report earnings around Aug 4, 2026. A full TMDX research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
Compare TransMedics Group, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For TransMedics Group, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full TMDX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on TransMedics Group, Inc., in minutes. 3 free reports included with every account — no credit card required.